Caribou Biosciences reported median progression-free survival of 17.1 months for its off-the-shelf CAR-T cell therapy candidate, adding evidence that the “universal” approach can match efficacy signals typically seen with autologous CAR-T products in lymphoma patients. The company said the data add to its case for comparable outcomes. The update positions off-the-shelf CAR-T as a path to faster access for patients who may not have time to manufacture individualized products. In practice, universal cell therapies can reduce logistical bottlenecks that delay treatment. Industry implications are focused on manufacturing and scalability: if the efficacy gap remains narrow while access improves, payers and providers may be more willing to shift toward standardized CAR-T production. Caribou’s update adds to a growing body of evidence that universal CAR-Ts are moving closer to the performance expectations set by autologous leaders.